Author: louiseakeroyd1
Japan – Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301 and Study304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician’s Choice [TPC], capecitabine, and vinorelbine, respectively) in patients living with metastatic breast cancer (mBC) whose tumors have low or no HER2 expression. These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022. The HER2-low breast cancer subtype is a ... Read more